EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Mortality Trends and Causes of Death in Myotonic Dystrophy Type 1 Patients From the UK Clinical Practice Research Datalink

Rotana Alsaggaf, Ruth M Pfeiffer, Emily E Pearce, Mark H Greene, Hanns Lochmuller, Shahinaz M Gadalla iD

Muscle & Nerve · 2025-02 · 71 (2) · 229-236

DOI: 10.1002/mus.28308 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Muscle & Nerve, online erschienen am 16.12.2024. Verfasst von Rotana Alsaggaf und 5 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Genetics Branch, Division of Cancer Epidemiology & Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, U…. Hauptthemen laut MEDLINE: Myotonic Dystrophy, Cause of Death. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Intramural Program of the National Cancer Institute, USA, Canada Foundation for Innovation, Canadian Institutes of Health Research and Muscular Dystrophy Canada.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction/Aim Patients with myotonic dystrophy type1 (DM1) have reduced lifespan. This study aimed to quantify mortality risks, and evaluate causes and time trends in DM1.

Methods

We identified 1021 DM1 patients and 15,104 matched DM1‐free controls from the United Kingdom (UK) Clinical Practice Research Datalink. We used Cox proportional hazards regression models to assess differences in all‐cause or cause‐specific mortality between DM1 patients and matched controls, and computed standardized mortality ratios (SMRs) for comparisons of DM1 patients with the UK general population.

Results

DM1 patients were at higher risk of death compared with matched DM1‐free controls (hazard ratio [HR] = 2.9, 95% confidence interval [CI] = 2.5–3.4) or the general UK population (SMR = 8.1, 95% CI = 7.3–9.1). The excess risk was primarily attributed to deaths from respiratory failure (HR = 26.7, p < 0.001), aspiration pneumonia (HR = 15.8, p < 0.001), arrythmia, and conduction defects (HR = 15.7, p < 0.001). No mortality risk difference between DM1 patients and matched DM1‐free cohort was noted for all cancers combined ( p = 0.52). No significant calendar time‐related changes in overall survival were seen for DM1 patients ( p trend = 0.19). In mortality cause‐specific analysis, and compared with patients diagnosed before 1993, death from cancer was on the rise (HR = 2.35, and 5.82 for patients diagnosed 1993–2003, and 2004–2016).

Discussion

Most DM1 patients died of known disease complications. This highlights the need for integrated clinical approaches with more careful and frequent monitoring.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myotonic DystrophyCause of DeathHumansUnited KingdomMaleFemaleMiddle AgedAdultAgedYoung AdultAdolescentProportional Hazards ModelsDatabases, FactualChildCase-Control Studies

Stichwörter der Autor:innen

CPRDcancermortalitymyotonic dystrophysurvival

Autor:innen und Institutionen

  • Clinical Genetics Branch, Division of Cancer Epidemiology & Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
  • Biostatistics Branch, Division of Cancer Epidemiology & Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
  • Children's Hospital of Eastern Ontario Research Institute, Division of Neurology, Department of Medicine, The Ottawa Hospital, and Brain and Mind Research Institute, University of Ottawa, Ottawa, Canada.

ORCID-Profile: Shahinaz M Gadalla

Förderung

  • Intramural Program of the National Cancer Institute, USA
  • Canada Foundation for Innovation
  • Canadian Institutes of Health Research and Muscular Dystrophy Canada
  • Intramural NIH HHS
  • Canada Research Chairs Program (Canada Research Chair in Neuromuscular Genomics and Health)
  • CIHR
  • Canadian Institutes of Health Research

Zitieren

APA

Alsaggaf, R., Pfeiffer, R. M., Pearce, E. E., Greene, M. H., Lochmuller, H., & Gadalla, S. M. (2025). Mortality Trends and Causes of Death in Myotonic Dystrophy Type 1 Patients From the UK Clinical Practice Research Datalink. Muscle & Nerve, 71(2), 229-236. https://doi.org/10.1002/mus.28308

Vancouver

Alsaggaf R, Pfeiffer RM, Pearce EE, Greene MH, Lochmuller H, Gadalla SM. Mortality Trends and Causes of Death in Myotonic Dystrophy Type 1 Patients From the UK Clinical Practice Research Datalink. Muscle & Nerve. 2025;71(2):229-236. doi:10.1002/mus.28308

BibTeX
@article{Alsaggaf2025,
  author = {Alsaggaf, Rotana and Pfeiffer, Ruth M and Pearce, Emily E and Greene, Mark H and Lochmuller, Hanns and Gadalla, Shahinaz M},
  title = {Mortality Trends and Causes of Death in Myotonic Dystrophy Type 1 Patients From the UK Clinical Practice Research Datalink},
  journal = {Muscle & Nerve},
  year = {2025},
  volume = {71},
  number = {2},
  pages = {229--236},
  doi = {10.1002/mus.28308}
}
Kostenlos starten →